Q-omics provides the consensus-scored ZNF418 profile across patient tissues and cancer cell-line models. ZNF418 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF418 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ZNF418 RNA expression shows 19,190 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where ZNF418 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF418 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF418 survival associations across molecular data types. ZNF418 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF418 RNA expression–survival associations across cancer types. High ZNF418 expression shows unfavorable associations in LGG and PRAD, but favorable associations in HNSC, KIRC, UCS and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF418 RNA expression.
This table summarizes ZNF418 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF418. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF418 shows lower tumor expression in KICH, COAD, HNSC, KIRP and UCEC and higher tumor expression in CHOL. The KICH box plot shows higher ZNF418 RNA expression in normal versus tumor tissue (log2 FC = −1.175, t-test p < 0.001).
This table shows molecular features associated with ZNF418 in patient tissues and cancer cell lines. In patient samples, ZNF418 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF418 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
